Published reports have suggested that SGLT2 inhibitors might prevent the development of NAFLD in rats and even improve the histological activity in obese mice with type 2 DM2 [7, 8]. Although two previous trials in human patients with DM2 and NAFLD showed positive effects for SGLT2 inhibitors on hepatic steatosis, they did not assay the drugs’ antifibrotic effects [9, 10]. The gene discussed is SLC5A2; the disease is myotonic dystrophy type 2.